4 results match your criteria: "HOPE Women's Cancer Centers[Affiliation]"
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.
Ann Oncol
April 2022
German Breast Group, c/o GBG Forschungs GmbH, Neu-Isenburg, Germany; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany.
Background: Primary analyses of the phase III BrighTNess trial showed addition of carboplatin with/without veliparib to neoadjuvant chemotherapy significantly improved pathological complete response (pCR) rates with manageable acute toxicity in patients with triple-negative breast cancer (TNBC). Here, we report 4.5-year follow-up data from the trial.
View Article and Find Full Text PDFCurrent advances in endocrine therapy options for premenopausal women with hormone receptor positive breast cancer.
Gynecol Oncol
October 2017
Department of Obstetrics and Gynecology, University of North Carolina-Chapel Hill, Chapel Hill, NC 27514, USA; HOPE Women's Cancer Centers, Asheville, NC 28804, USA. Electronic address:
Surgical and Locoregional Treatment of DCIS and Early-Invasive Breast Cancer.
Clin Obstet Gynecol
December 2016
*Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, Chapel Hill †Mission Health, Mission Cancer-Hope Women's Cancer Centers, Asheville, North Carolina.
Surgical and radiation therapy for DCIS and early stage 1 and 2 invasive breast cancer is detailed and described.
View Article and Find Full Text PDFSurgical and local-regional treatment of "early" invasive breast cancer.
Clin Obstet Gynecol
March 2011
Department of OB/GYN, University of North Carolina-Chapel Hill, HOPE Women's Cancer Centers, Asheville, North Carolina, USA.